{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:36:43Z","timestamp":1771486603544,"version":"3.50.1"},"reference-count":25,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Patients with hematologic malignancies are at high risk of exacerbated condition and higher mortality from coronavirus disease 2019 (COVID-19). Bamlanivimab, casirivimab\/imdevimab combination, and sotrovimab are monoclonal antibodies (mABs) that can reduce the risk of COVID-19-related hospitalization. Clinical effectiveness of bamlanivimab and casirivimab\/imdevimab combination has been shown for the Delta variant (B.1.617.2), but the effectiveness of the latter treatment against the Omicron variant (B.1.1.529) has been suggested to be reduced. However, the tolerability and clinical usage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific mABs in patients with hematologic malignancies are less specified. We present a retrospective case series analysis of all SARS-CoV-2-infected patients with hematologic malignancies who received SARS-CoV-2-specific mABs at our facility between February and mid-December 2021. A total of 13 COVID-19 patients (pts) with at least one malignant hematologic diagnosis received SARS-CoV-2-specific mABs at our facility, with 3 pts receiving bamlanivimab and 10 pts receiving casirivimab\/imdevimab combination. We observed SARS-CoV-2 clearance in five cases. Furthermore, we observed a reduction in the necessity for oxygen supplementation in five cases where the application was administered off-label. To the best of our knowledge, we present the largest collection of anecdotal cases of SARS-CoV-2-specific monoclonal antibody use in patients with hematological malignancies. Potential benefit of mABs may be reduced duration and\/or clearance of persistent SARS-CoV-2 infection.<\/jats:p>","DOI":"10.3390\/curroncol29040188","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T21:27:51Z","timestamp":1648416471000},"page":"2312-2325","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series"],"prefix":"10.3390","volume":"29","author":[{"given":"G\u00f6ran Ramin","family":"Boeckel","sequence":"first","affiliation":[{"name":"Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, 48149 Muenster, Germany"},{"name":"Department of Medicine D for Nephrology and Rheumatology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke Dorothea","family":"H\u00f6lscher","sequence":"additional","affiliation":[{"name":"Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christin","family":"B\u00fcrger","sequence":"additional","affiliation":[{"name":"Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torid","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Krekeler","sequence":"additional","affiliation":[{"name":"Department of Medicine A (Hematology, Oncology, Hemostaseology and Pulmonology), University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0178-1729","authenticated-orcid":false,"given":"Evgenii","family":"Shumilov","sequence":"additional","affiliation":[{"name":"Department of Medicine A (Hematology, Oncology, Hemostaseology and Pulmonology), University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Reicherts","sequence":"additional","affiliation":[{"name":"Department of Medicine A (Hematology, Oncology, Hemostaseology and Pulmonology), University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalen","family":"Bleckmann","sequence":"additional","affiliation":[{"name":"Department of Medicine A (Hematology, Oncology, Hemostaseology and Pulmonology), University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Medicine A (Hematology, Oncology, Hemostaseology and Pulmonology), University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-7924","authenticated-orcid":false,"given":"Richard","family":"Vollenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2757-4755","authenticated-orcid":false,"given":"Phil-Robin","family":"Tepasse","sequence":"additional","affiliation":[{"name":"Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, 48149 Muenster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial","volume":"324","author":"Tomazini","year":"2020","journal-title":"Jama"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1001\/jama.2021.18295","article-title":"Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive without Life Support in Adults with COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial","volume":"326","author":"Munch","year":"2021","journal-title":"Jama"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100775","DOI":"10.1016\/j.blre.2020.100775","article-title":"When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities","volume":"47","author":"Wang","year":"2021","journal-title":"Blood Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jama.2021.8828","article-title":"Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial","volume":"326","author":"Cohen","year":"2021","journal-title":"Jama"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"ofab546","DOI":"10.1093\/ofid\/ofab546","article-title":"Bamlanivimab Efficacy in Older and High-BMI Outpatients with COVID-19 Selected for Treatment in a Lottery-Based Allocation Process","volume":"Volume 8","author":"Rubin","year":"2021","journal-title":"Open Forum Infectious Diseases"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"ref_12","unstructured":"Koch-Institute, R. (2022, February 22). Falldefinitionen des Robert Koch-Instituts zur \u00dcbermittlung von Erkrankungs-oder Todesf\u00e4llen und Nachweisen von Krankheitserregern Stand 23.12.2020. Available online: https:\/\/www.rki.de\/EN\/Content\/Health_Monitoring\/JoHM_en\/allgemein_en\/authors\/Citation_style\/citation_style_node.html."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Drouin, A.C., Theberge, M.W., Liu, S.Y., Smither, A.R., Flaherty, S.M., Zeller, M., Geba, G.P., Reynaud, P., Rothwell, W.B., and Luk, A.P. (2021). Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail. Viruses, 13.","DOI":"10.3390\/v13071202"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12941-021-00491-2","article-title":"Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: Successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy","volume":"20","author":"Taha","year":"2021","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.17756","article-title":"Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia","volume":"196","author":"Saultier","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_16","first-page":"Cd013825","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","volume":"9","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_18","first-page":"665","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial","volume":"399","author":"Horby","year":"2021","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial","volume":"327","author":"Sarkar","year":"2022","journal-title":"Jama"},{"key":"ref_20","first-page":"865","article-title":"Clinical Practice Guideline: Recommendations on the In-Hospital Treatment of Patients with COVID-19","volume":"118","author":"Kluge","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_21","unstructured":"European Medicines Agency (EMA) (2022, February 23). Ronapreve Casirivimab\/Imdevimab. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ronapreve."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e05236","DOI":"10.1002\/ccr3.5236","article-title":"Clinically suspected myocarditis in COVID-19 patients: Case series and review of the literature","volume":"9","author":"Amin","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"108460","DOI":"10.1016\/j.diabres.2020.108460","article-title":"Characteristics of patients with diabetes hospitalised for COVID-19 infection-a brief case series report","volume":"169","author":"Conway","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2021.11.040","article-title":"Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)\u2014highlights Africa\u2019s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts","volume":"114","author":"Petersen","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., and Helfritz, F.A. (2021). Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies. medRxiv.","DOI":"10.1101\/2021.12.07.21267432"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/4\/188\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:44:04Z","timestamp":1760136244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/4\/188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,26]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["curroncol29040188"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29040188","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,26]]}}}